Lipid-lowering therapy and long-term survival in heart transplantation

American Journal of Cardiology

Volumn 80, Issue 6, 1997, Pages 802-805

  Stapleton, Dwight D ^a   Mehra, Mandeep R ^a   Dumas, Debi ^a   Smart, Frank W ^a   Milani, Richard V ^a   Lavie, Carl J ^a   Ventura, Hector O ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALLOGRAFT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; ANTILIPEMIC AGENTS; CHOLESTEROL; COHORT STUDIES; FEMALE; GEMFIBROZIL; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRIGLYCERIDES;

EID: 0031572271     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00524-9     Document Type: Article

References (13)

1. 1. Winters GL, Kendall TJ, Radio SJ, Wilson JE, Costanzo-Nordin MR, Switzer BL, Remmenga JA, McManus BM. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant 1990;9:364-371.
2. 2. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, Stinson EB. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987;76(suppl V):V-56-V-61.
3. 3. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J 1995;129:791-798.
4. 4. Valantine HA. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995;14(6)part 2:S234-S237.
5. 5. Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 1995;26: 1537-1544.
6. 6. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med 1995;333:621-627.
7. 7. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
8. 8. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
9. 9. Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transplant 1990;9:587-593.
10. 10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987;317:1237-1245.
11. 11. Gao SZ, Alerman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988;12:334-340.
12. 12. Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation 1989;80(suppl):III-111-115.
13. 13. Valantine H, Hunt S, Gamberg P, Miller J, Luikart H. Impact of cyclosporine dose on long-term outcome after heart transplantation. Transpl Proc 1994;26: 2710-2712.